Human Pathology
Volume 41, Issue 2 , Pages 208-213 , February 2010

Immunohistochemical analysis for Sox9 reveals the cartilaginous character of chondroblastoma and chondromyxoid fibroma of the bone

  • Eiichi Konishi, MD, PhD

      Affiliations

    • Department of Pathology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
    • Department of Laboratory Medicine, National Hospital Organization Osaka Medical Center, Osaka 540-0006, Japan
    • Corresponding Author InformationCorresponding author. Department of Pathology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566 Japan.
    • ,
  • Yasuaki Nakashima, MD, PhD

      Affiliations

    • Laboratory of Anatomic Pathology, Kyoto University Hospital, Kyoto 606-8507, Japan
    • ,
  • Yoko Iwasa, MD, PhD

      Affiliations

    • Department of Pathology, Graduate School of Medicine, Osaka City University, Osaka 545-8586, Japan
    • Department of Laboratory Medicine, National Hospital Organization Osaka Medical Center, Osaka 540-0006, Japan
    • ,
  • Ryuta Nakao, MD

      Affiliations

    • Department of Pathology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
    • ,
  • Akio Yanagisawa, MD, PhD

      Affiliations

    • Department of Pathology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

Received 18 May 2009 ,Revised 21 July 2009 ,Accepted 22 July 2009.

References 

  1. In:  Fletcher C,  Unni KK,  Mertens F editor. World Health Organization classification of tumors. Pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002;p. 226
  2. Jaffe H, Lichtenstein L. Benign chondroblastoma of bone; a reinterpretation of the so-called calcifying or chondromatous giant cell tumor. Am J Pathol. 1942;18:969–983
  3. Unni KK, Inwards C, Bridge J, Kindblom L, Wold L. Chondroblastoma. In:  Silverberg SG, et al. editor. AFIP atlas of tumor pathology. 4th series. Tumors of the bones and joints. Silver Spring: ARP Press; 2005;p. 61–67
  4. Jaffe H, Lichtenstein L. Chondromyxoid fibroma of bone: a distinctive benign tumor likely to be mistaken especially for chondrosarcoma. Arch Pathol. 1948;45:541–551
  5. Unni KK, Inwards C, Bridge J, Kindblom L, Wold L. Chondromyxoid fibroma. In:  Silverberg SG, et al. editor. AFIP atlas of tumor pathology. 4th series. Tumors of the bones and joints. Silver Spring: ARP Press; 2005;p. 67–73
  6. Ushigome S, Takakuwa T, Shinagawa T, Takagi M, Kishimoto H, Mori N. Ultrastructure of cartilaginous tumors and S-100 protein in the tumors. With reference to the histogenesis of chondroblastoma, chondromyxoid fibroma and mesenchymal chondrosarcoma. Acta Pathol Jpn. 1984;34:1285–1300
  7. Weiss AP, Dorfman HD. S-100 protein in human cartilage lesions. J Bone Joint Surg Am. 1986;68:521–526
  8. Okajima K, Honda I, Kitagawa T. Immunohistochemical distribution of S-100 protein in tumors and tumor-like lesions of bone and cartilage. Cancer. 1988;61:792–799
  9. Edel G, Ueda Y, Nakanishi J, Brinker KH, Roessner A, Blasius S, et al. Chondroblastoma of bone. A clinical, radiological, light and immunohistochemical study. Virchows Arch A Pathol Anat Histopathol. 1992;421:355–366
  10. Hasegawa T, Seki K, Yang P, Hirose T, Hizawa K, Wada T, et al. Differentiation and proliferative activity in benign and malignant cartilage tumors of bone. Hum Pathol. 1995;26:838–845
  11. Park HR, Park YK, Jang KT, Unni KK. Expression of collagen type II, S100B, S100A2 and osteocalcin in chondroblastoma and chondromyxoid fibroma. Oncol Rep. 2002;9:1087–1091
  12. Mii Y, Miyauchi Y, Morishita T, Miura S, Honoki K, Aoki M, et al. Ultrastructural cytochemical demonstration of proteoglycans and calcium in the extracellular matrix of chondroblastomas. Hum Pathol. 1994;25:1290–1294
  13. Aigner T, Loos S, Inwards C, Perris R, Perissinotto D, Unni KK, et al. Chondroblastoma is an osteoid-forming, but not cartilage-forming neoplasm. J Pathol. 1999;189:463–469
  14. Nielsen GP, Keel SB, Dickersin GR, Selig MK, Bhan AK, Rosenberg AE. Chondromyxoid fibroma: a tumor showing myofibroblastic, myochondroblastic, and chondrocytic differentiation. Mod Pathol. 1999;12:514–517
  15. Romeo S, Eyden B, Prins FA, Briaire-de Bruijn IH, Taminiau AH, Hogendoorn PC. TGF-beta1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone. J Pathol. 2006;208:26–34
  16. Soder S, Inwards C, Muller S, Kirchner T, Aigner T. Cell biology and matrix biochemistry of chondromyxoid fibroma. Am J Clin Pathol. 2001;116:271–277
  17. Romeo S, Bovee JV, Grogan SP, et al. Chondromyxoid fibroma resembles in vitro chondrogenesis, but differs in expression of signalling molecules. J Pathol. 2005;206:135–142
  18. van de Wetering M, Clevers H. Sequence-specific interaction of the HMG box proteins TCF-1 and SRY occurs within the minor groove of a Watson-Crick double helix. EMBO J. 1992;11:3039–3044
  19. Dubin RA, Ostrer H. Sry is a transcriptional activator. Mol Endocrinol. 1994;8:1182–1192
  20. Giese K, Kingsley C, Kirshner JR, Grosschedl R. Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1–induced DNA bending and multiple protein-protein interactions. Genes Dev. 1995;9:995–1008
  21. Foster JW, Dominguez-Steglich MA, Guioli S, et al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature. 1994;372:525–530
  22. Wagner T, Wirth J, Meyer J, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell. 1994;79:1111–1120
  23. Wright E, Hargrave MR, Christiansen J, et al. The Sry-related gene Sox9 is expressed during chondrogenesis in mouse embryos. Nat Genet. 1995;9:15–20
  24. Ng LJ, Wheatley S, Muscat GE, et al. SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse. Dev Biol. 1997;183:108–121
  25. Zhao Q, Eberspaecher H, Lefebvre V, de Crombrugghe B. Parallel expression of Sox9 and Col2a1 in cells undergoing chondrogenesis. Dev Dyn. 1997;209:377–386
  26. Healy C, Uwanogho D, Sharpe PT. Regulation and role of Sox9 in cartilage formation. Dev Dyn. 1999;215:69–78
  27. de Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W. Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol. 2000;19:389–394
  28. Lefebvre V, Behringer RR, de Crombrugghe B. L-Sox5, Sox6 and Sox9 control essential steps of the chondrocyte differentiation pathway. Osteoarthritis Cartilage. 2001;9:S69–S75
  29. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16:2813–2828
  30. Lefebvre V, Smits P. Transcriptional control of chondrocyte fate and differentiation. Birth Defects Res C Embryo Today. 2005;75:200–212
  31. Wehrli BM, Huang W, de Crombrugghe B, Ayala AG, Czerniak B. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol. 2003;34:263–269
  32. Veras EF, Santamaria IB, Luna MA. Sinonasal chondromyxoid fibroma. Ann Diagn Pathol. 2009;13:41–46[Electronic publication 2007 Oct 24]
  33. Romeo S, Bovee JV, Jadnanansing NA, Taminiau AH, Hogendoorn PC. Expression of cartilage growth plate signalling molecules in chondroblastoma. J Pathol. 2004;202:113–120
  34. Akiyama H, Lyons JP, Mori-Akiyama Y, et al. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev. 2004;18:1072–1087

PII: S0046-8177(09)00274-3

doi: 10.1016/j.humpath.2009.07.014

Human Pathology
Volume 41, Issue 2 , Pages 208-213 , February 2010

Article Tools

* Image Usage & Resolution